430 related articles for article (PubMed ID: 25919121)
1. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT; Bishop JR
Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.
Trzepacz PT; Williams DW; Feldman PD; Wrishko RE; Witcher JW; Buitelaar JK
Eur Neuropsychopharmacol; 2008 Feb; 18(2):79-86. PubMed ID: 17698328
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
7. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
Brown JT; Abdel-Rahman SM; van Haandel L; Gaedigk A; Lin YS; Leeder JS
Clin Pharmacol Ther; 2016 Jun; 99(6):642-50. PubMed ID: 26660002
[TBL] [Abstract][Full Text] [Related]
8. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
[TBL] [Abstract][Full Text] [Related]
9. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G; Li GF; Markowitz JS
J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
[TBL] [Abstract][Full Text] [Related]
12. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
Brown JT
Methods Mol Biol; 2022; 2547():427-436. PubMed ID: 36068472
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CYP2D6 genotype and response to tetrabenazine.
Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
Upadhyaya H; Kratochvil C; Ghuman J; Camporeale A; Lipsius S; D'Souza D; Tanaka Y
J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):799-809. PubMed ID: 25265343
[TBL] [Abstract][Full Text] [Related]
18. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
ter Laak MA; Temmink AH; Koeken A; van 't Veer NE; van Hattum PR; Cobbaert CM
Pediatr Neurol; 2010 Sep; 43(3):159-62. PubMed ID: 20691935
[TBL] [Abstract][Full Text] [Related]
19. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
Fu D; Guo HL; Hu YH; Chen F
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]